| White, Perrin C |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
NCT05743244: Janus Kinase (JAK) Inhibitors to Preserve C-Peptide Production in New Onset Type 1 Diabetes (T1D) |
|
|
| Recruiting | 2 | 78 | US | Abrocitinib 200 MG Oral Tablet, CIBINQO, Ritlecitinib, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Pfizer | Diabetes Mellitus, Type 1 | 06/26 | 06/27 | | |
NCT03929601: Rituximab-pvvr and Abatacept Vs Rituximab-pvvr Alone in New Onset Type 1 Diabetes |
|
|
| Recruiting | 2 | 74 | US, RoW | Rituximab-pvvr, Ruxience, Abatacept, Orencia, Sterile Sodium Chloride, 0.9% Sodium Chloride Water for Injection | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Institutes of Health (NIH) | Type 1 Diabetes Mellitus | 10/27 | 10/29 | | |
| Active, not recruiting | 2 | 101 | US, RoW | Antithymocyte Globulin, Thymoglobulin, Placebo (for ATG) | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 12/28 | 12/29 | | |
TOPPLE T1D, NCT04279613: A Multiple Ascending Dose Trial Investigating Safety, Tolerability and Pharmacokinetics of NNC0361-0041 |
|
|
| Completed | 1 | 47 | US | NNC0361-0041, Placebo | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), Novo Nordisk A/S | Type I Diabetes | 08/23 | 04/24 | | |
NCT02574910: Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 |
|
|
| Suspended | 1 | 36 | US | Abiraterone acetate, Zytiga | University of Texas Southwestern Medical Center, Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), University of Michigan, Children's Hospital Los Angeles | Congenital Adrenal Hyperplasia | 01/25 | 01/25 | | |
NCT04540536: Feasibility and Effectiveness of Real-time, Remote Continuous Glucose Monitoring in Adolescents with Poorly Controlled Type 1 Diabetes |
|
|
| Completed | N/A | 20 | US | Continuous Glucose Monitoring, Secure texting | University of Texas Southwestern Medical Center, DexCom, Inc. | Diabetes Mellitus, Type 1, Noncompliance, Patient | 12/24 | 12/24 | | |
| Recruiting | N/A | 75000 | Europe, Canada, US, RoW | | University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), American Diabetes Association, National Institute of Allergy and Infectious Diseases (NIAID), National Center for Research Resources (NCRR) | Diabetes Mellitus, Type 1 | 07/25 | 07/25 | | |
| Eugster, Erica |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
| Lei, Ting |
NCT06023147: A Real-world Study of the Short-term Efficacy and Safety of E-TACE in Patients With Hepatocellular Carcinoma (HCC) |
|
|
| Not yet recruiting | N/A | 298 | RoW | E-TACE | Xuhua Duan | Hepatocellular Carcinoma | 09/24 | 09/25 | | |
| Recruiting | N/A | 200 | RoW | antibiotic-impregnated catheter | Integra LifeSciences Corporation | Hydrocephalus | 07/26 | 12/26 | | |
NCT05755516: Efficacy and Safety of the Self-expanding Intracranial Stent (Tonbridge) for Endovascular Treatment of Intracranial Aneurysms |
|
|
| Active, not recruiting | N/A | 204 | RoW | Self-expanding Intracranial Stent (Tonbridge), LVIS and LVIS Jr. (MicroVention) | Zhuhai Tonbridge Medical Tech. Co., Ltd. | Intracranial Aneurysm | 10/24 | 04/25 | | |
| Yu, Xuefeng |
NCT06697886: A Study of the Efficacy and Safety of Antiwei Granules in the Treatment of Common Cold |
|
|
| Recruiting | 3 | 480 | RoW | Antiwei Granules, Antiwei Granules Placebo | Tasly Pharmaceutical Group Co., Ltd | Common Cold | 06/25 | 07/25 | | |
| Active, not recruiting | 2 | 145 | Europe, Canada, Japan, US, RoW | GSK3858279, Placebo | GlaxoSmithKline | Pain | 10/24 | 01/25 | | |
NCT03766334: Efficacy and Safety of Highland Barley Diet on Glucose Variability in Patients With Type 1 Diabetes Mellitus |
|
|
| Withdrawn | N/A | 80 | RoW | Highland Barley Diet | Huazhong University of Science and Technology | Type1 Diabetes Mellitus | 10/23 | 12/23 | | |
NCT05765097: Clinical Application of an Open-source Artificial Pancreas System in Adult Inpatients With Diabetes |
|
|
| Completed | N/A | 10 | RoW | Artificial pancreas treatment | Huazhong University of Science and Technology | Diabetes Mellitus | 05/23 | 12/23 | | |
NCT06295289: Hybrid Closed-loop Insulin Delivery System in Perioperative Diabetic Patients: an Open-label, Randomized Controlled Trial |
|
|
| Recruiting | N/A | 54 | RoW | Hybrid Closed-loop Insulin Delivery System, Insulin pump | Huazhong University of Science and Technology | Diabetes Mellitus | 10/24 | 12/24 | | |
| Luo, Ailin |
NCT04908553: Study on the Safety and Effectiveness of Remimazolam Tosilate for Injection for Short-term Elective Surgery in Adults |
|
|
| Completed | 4 | 650 | RoW | Remimazolam Tosilate for Injection 0.1mg/kg, low dose group, Remimazolam Tosilate for Injection 0.15mg/kg, medium dose group, Remimazolam Tosilate for Injection 0.2mg/kg, high dose group | Tongji Hospital | Hypotension During Surgery | 12/22 | 01/23 | | |
NCT06674226: Effects of Ciprofol on Postoperative Delirium and Outcomes in Elderly Patients Undergoing Major Thoracic Surgery |
|
|
| Recruiting | 4 | 214 | RoW | Ciprofol, Propofol | Wang Tianlong, Xiangya Hospital of Central South University, The Third Xiangya Hospital of Central South University, The First Hospital of Hebei Medical University, The First Affiliated Hospital of Nanchang University, Tongji Hospital, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Postoperative Delirium (POD) | 06/26 | 06/26 | | |
NCT04829409: The Effects of Three Different Ultrasound-guided Nerve Blocks in VATS |
|
|
| Recruiting | N/A | 90 | RoW | Paravertebral block, ESP block, MTP block | Huazhong University of Science and Technology | Thoracic Anesthesia, Nerve Block, Pain, Acute | 10/22 | 12/22 | | |
| Completed | N/A | 336 | RoW | Esketamine, Es group, Normal saline, Ns group | Ailin Luo, Maternal and Child Health Hospital of Hubei Province, Jingmen No.1 People's Hospital | Esketamine, Postpartum Depression | 03/24 | 03/24 | | |
NCT05810363: The Safety of Etomidate - Propofol Mixture vs Propofol in Total Intravenous Anesthesia During Abdominal Surgery |
|
|
| Recruiting | N/A | 468 | RoW | Etomidate - propofol mixture, EP, Propofol, P | Ailin Luo | Etomidate, Hypotension | 05/24 | 08/24 | | |
NCT06009991: The Dose Range of Remimazolam Besylate in Different Age Groups |
|
|
| Recruiting | N/A | 1876 | RoW | Remimazolam besylate, Propofol | Tongji Hospital, Renmin Hospital of Wuhan University, Wuhan University, The General Hospital of Central Theater Command, Taihe Hospital, Yichang Central People's Hospital, Jingzhou Central Hospital, Beijing Shijitan Hospital, Capital Medical University, The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, First Affiliated Hospital of Fujian Medical University, Tianjin Nankai Hospital, Sichuan Provincial People's Hospital, Shanxi Bethune Hospital | Remimazolam, Anesthesia | 09/25 | 12/25 | | |
| Zhou, JianFeng |
BENCH, NCT04939142: A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM) |
|
|
| Active, not recruiting | 3 | 150 | RoW | SVd (Selinexor+Bortezomib+dexamethasone), Vd (Bortezomib+dexamethasone) | Antengene Corporation | Relapsed or Refractory Multiple Myeloma | 07/24 | 10/24 | | |
NCT04453345: TPM Regimen (Thalidomide, Prednisone and Methotrexate) in LGLL |
|
|
| Recruiting | 2/3 | 42 | RoW | thalidomide + prednisone + methotrexate, TPM regimen | Institute of Hematology & Blood Diseases Hospital, The First Affiliated Hospital of Nanchang University, First Affiliated Hospital of Guangxi Medical University, Henan Cancer Hospital, First Hospital of Jilin University, Central South University, Tianjin First Central Hospital | T-LGL Leukemia, Clpd-Nk | 05/23 | 05/25 | | |
| Recruiting | 2 | 32 | RoW | Anlotinib, anlotinib hydrochloride, Penpulimab, AK105 | Peking Union Medical College Hospital | Colorectal Cancer | 08/22 | 08/23 | | |
NCT04291248: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor |
|
|
| Not yet recruiting | 2 | 138 | RoW | AK105, Anlotinib | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | MSI-H or dMMR Advanced Solid Tumors | 12/22 | 12/22 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05320081: Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma |
|
|
| Recruiting | 2 | 30 | RoW | CD30 CAR-T, Camrelizumab | Huazhong University of Science and Technology, The First Affiliated Hospital of Nanchang University | Lymphoma, Relapse/Recurrence | 12/23 | 06/24 | | |
NAUTICALCRC, NCT05004350: A Study Evaluating the Combination of Encorafenib and Cetuximab Versus Irinotecan/Cetuximab or Infusional 5-fluorouracil (5-FU)/Folinic Acid (FA)/Irinotecan (FOLFIRI)/Cetuximab in Chinese Patients With BRAF V600E Mutant Metastatic Colorectal Cancer. |
|
|
| Active, not recruiting | 2 | 103 | RoW | Encorafenib, Braftovi®, PF-07263896, W0090, LGX818, ONO-7702, Cetuximab, Erbitux®, C225, FOLFIRI, Folinic acid + Fluorouracil + Irinotecan | Pierre Fabre Medicament, Merck KGaA, Darmstadt, Germany | BRAF V600E, Metastatic Colorectal Cancer | 12/23 | 01/25 | | |
NCT04888442: Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL |
|
|
| Recruiting | 1 | 18 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | 01/22 | 03/22 | | |
NCT04767308: Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies |
|
|
| Not yet recruiting | 1 | 18 | NA | CT125A cells, Cyclophosphamide, fludarabine | Huazhong University of Science and Technology, Shanghai IASO Biotechnology Co., Ltd | CD5+ Relapsed/Refractory Hematopoietic Malignancies, Chronic Lymphocytic Leukemia (CLL), Mantle Cell Lymphoma (MCL), Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), Peripheral T-cell Lymphomas (PTCL) | 09/23 | 12/23 | | |
CARTinNS, NCT04561557: Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Inflammatory Diseases of the Nervous System |
|
|
| Recruiting | 1 | 36 | RoW | CT103A cells, Cyclophosphamide and fludarabine | Tongji Hospital, Nanjing IASO Biotechnology Co., Ltd. | Autoimmune Diseases, Autoimmune Diseases of the Nervous System, Neuromyelitis Optica Spectrum Disorder, Myasthenia Gravis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Idiopathic Inflammatory Myopathies, Multiple Sclerosis, Autoimmune Encephalitis, Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD), POEMS Syndrome | 02/27 | 05/27 | | |
NCT03491605: Surveillance and Tracking the Outcomes of Chronic Latent EBV Infection |
|
|
| Recruiting | N/A | 10000 | RoW | peripheral EBV-DNA load | Huazhong University of Science and Technology | EBV Infection | 12/24 | 12/29 | | |
| luo, xiaoping |
| Recruiting | 4 | 80 | RoW | Leuprorelin Acetate Depot 3M, Leuprolide acetate Depot 3M | Takeda, Takeda | Central Precocious Puberty | 05/25 | 05/25 | | |
NCT05353192: A Study to Evaluate the Efficacy and Safety of Recombinant Human Growth Hormone in Children With Achondroplasia |
|
|
| Recruiting | 4 | 38 | RoW | Recombinant human growth hormone | GeneScience Pharmaceuticals Co., Ltd., Children's Hospital of Fudan University, Tongji Hospital, Children's Hospital of Nanjing Medical University, Jiangxi Province Children's Hospital, Chengdu Women's and Children's Central Hospital, Shandong Provincial Hospital, Shengjing Hospital, Shanghai Children's Hospital, Children's Hospital of The Capital Institute of Pediatrics, West China Second University Hospital, Sichuan University | Achondroplasia | 02/25 | 02/25 | | |
NCT05144035: A Real World Study of the Effect of Early PEG-rhGH Therapy on Cognitive Development of SGA Infants |
|
|
| Recruiting | 4 | 138 | RoW | PEG-rhGH, jintrolong | Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd. | Small for Gestational Age Infant, Growth Hormone Treatment, Cognitive Developmental Disorder | 12/25 | 06/26 | | |
NCT04633057: A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone Deficiency |
|
|
| Completed | 3 | 168 | RoW | TJ101, NordiFlex | TJ Biopharma Co., Ltd. | Pediatric Growth Hormone Deficiency | 07/23 | 07/23 | | |
| Completed | 3 | 20 | RoW | Velaglucerase Alfa, VPRIV | Takeda, Takeda | Gaucher Disease | 08/24 | 08/24 | | |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
NCT04513171: Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children |
|
|
| Completed | 2/3 | 434 | RoW | Y-shape pegylated somatropin, Norditropin®, Norditropin | Xiamen Amoytop Biotech Co., Ltd., Tongji Hospital | Growth Hormone Deficiency | 06/23 | 07/23 | | |
NCT03255694: A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature |
|
|
| Active, not recruiting | 2 | 360 | RoW | PEG-somatropin, Polyethylene Glycol Recombinant Human Somatropin Injection | GeneScience Pharmaceuticals Co., Ltd., Tongji Hospital, The First Hospital of Jilin University, Affiliated Hospital of Jiangnan University, The First Affiliated Hospital with Nanjing Medical University, Shanghai Children's Hospital, The Children's Hospital of Zhejiang University School of Medicine, Children's Hospital of Fudan University | Dwarfism | 06/30 | 06/30 | | |
| Completed | N/A | 743 | RoW | | Changchun GeneScience Pharmaceutical Co., Ltd., Tongji Hospital | Turner Syndrome | 06/23 | 06/23 | | |
| Recruiting | N/A | 15 | RoW | Nitisinone, Orfadin® | Swedish Orphan Biovitrum | Hereditary Tyrosinemia, Type I | 06/27 | 06/27 | | |
NCT05137301: Performance of the Diagnostic Value of Bone Age Assessment Software Based on Deep Learning in Chinese Children |
|
|
| Recruiting | N/A | 1000 | RoW | X-ray bone age instrument | Tongji Hospital, GeneScience Pharmaceuticals Co., Ltd. | Endocrine Diseases | 12/24 | 12/24 | | |
NCT06110910: Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS) |
|
|
| Recruiting | N/A | 10000 | RoW | Polvethylene glycol recombinant human growth hormone injection (PEG-rhGH) or recombinanthuman growth hormone injection (rhGH), PEG-rhGH or rhGH | Xiaoping Luo | Childhood Short Stature | 12/27 | 12/27 | | |
| Zhu, Xu |
| Not yet recruiting | 2 | 66 | NA | cTACE-HAIC, OXRI | Beijing Cancer Hospital | Transarterial Chemoembolization, Hepatocellular Carcinoma | 10/21 | 10/22 | | |
NCT05406206: Hepatic Arterial Infusion Chemotherapy With Fruquintinib for Colorectal Cancer Liver Metastases As Third-line Therapy |
|
|
| Recruiting | 2 | 27 | RoW | Fruquintinib, HMPL-013, Hepatic Arterial Infusion Chemotherapy, HAIC | Beijing Cancer Hospital | Advanced Colorectal Carcinoma, Liver Metastasis Colon Cancer | 07/23 | 10/24 | | |
NCT04479527: Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma |
|
|
| Not yet recruiting | 2 | 34 | NA | Camrelizumab, Apatinib Mesylas | Beijing Cancer Hospital, Jiangsu Hengrui Pharmaceutical Co., Ltd. | Hepatocellular Carcinoma | 08/23 | 12/23 | | |
NCT05877001: The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases |
|
|
| Recruiting | 2 | 20 | RoW | Tislelizumab, BGB-A317, Regorafenib, BAY73-4506, HAIC | Peking University Cancer Hospital & Institute | Colorectal Liver Metastases | 07/24 | 03/25 | | |
NCT06057571: Study of TT-00420 (Tinengotinib) in Subjects With Cholangiocarcinoma Who Failed or Relapsed to Chemotherapy and FGFR Inhibitor |
|
|
| Recruiting | 2 | 50 | RoW | TT-00420 (tinengotinib) | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma Metastatic | 06/25 | 10/25 | | |
NCT05678270: A Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma |
|
|
| Recruiting | 2 | 70 | RoW | ICP-192 | Beijing InnoCare Pharma Tech Co., Ltd. | Intrahepatic Cholangiocarcinoma (ICC) | 05/26 | 12/26 | | |
| Recruiting | 1/2 | 222 | RoW | SHR-1701, Famitinib | Jiangsu HengRui Medicine Co., Ltd. | Solid Tumor | 12/22 | 10/23 | | |
NCT05862181: The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma |
|
|
| Recruiting | N/A | 200 | RoW | DEB-TACE plus HAIC or HAIC alone | Peking University Cancer Hospital & Institute | Advanced Hepatocellular Carcinoma (HCC) | 07/23 | 12/23 | | |
NCT05889325: To Evaluate the Performance of HepaSphere Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy on Unresectable Colorectal Liver Metastases |
|
|
| Not yet recruiting | N/A | 100 | RoW | DEB-TACE plus HAIC | Peking University Cancer Hospital & Institute | Colorectal Liver Metastases (CRCLM) | 09/23 | 11/23 | | |
NCT06109805: Plasma Metabolic Biomarkers for Gastric Cancer Diagnosis |
|
|
| Recruiting | N/A | 1200 | RoW | Gastric cancer | Beijing Friendship Hospital | Gastric Cancer | 10/24 | 12/24 | | |
| Zeng, Hesong |
| Not yet recruiting | N/A | 500 | RoW | Assessment of plaque morphology, structure, and stability in non-culprit lesions | Chinese PLA General Hospital | Coronary Arterial Disease (CAD), Acute Coronary Syndromes | 12/27 | 12/31 | | |
| Dai, Huaping |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT05288179: Efficacy and Safety of Pirfenidone Capsules in the Treatment of Pneumoconiosis |
|
|
| Not yet recruiting | 3 | 272 | NA | Pirfenidone Capsules, F647, placebo capsules, N | Beijing Continent Pharmaceutical Co, Ltd. | Pneumoconiosis | 09/24 | 09/25 | | |
NCT05722964: Study on Intravenous Injection of SHR-1906 in the Treatment of Idiopathic Pulmonary Fibrosis |
|
|
| Recruiting | 2 | 108 | RoW | SHR-1906, Placebo | Guangdong Hengrui Pharmaceutical Co., Ltd | Idiopathic Pulmonary Fibrosis | 05/24 | 05/24 | | |
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
NCT06655090: Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in China |
|
|
| Recruiting | N/A | 10000 | RoW | | Dai Huaping, The First Affiliated Hospital of Guangzhou Medical University, Nankai University, Jilin University, Shanghai Pulmonary Hospital, Shanghai, China, Shanghai Chest Hospital, Institute of Basic Medical Sciences CAMS, Tongji Hospital, National Institute for Occupational Health and Poison Control, Infervision Medical Technology Company Limited | Interstitial Lung Disease (ILD) | 11/24 | 11/27 | | |
| Recruiting | N/A | 800 | RoW | | Dai Huaping | Idiopathic Pulmonary Fibrosis | 06/23 | 06/23 | | |
| Smith, Joshua |
| Active, not recruiting | 3 | 319 | US | Afrezza, Technosphere Insulin, Rapid-acting Insulin Analog, insulin aspart, insulin lispro, insulin glulisine, Novolog®, Fiasp®, Humalog®, Admelog®, Apidra®, Basal Insulin, insulin glargine, insulin degludec, insulin detemir, Lantus®, Abasaglar®, Basaglar®, Semglee®, Toujeo®, Tresiba®, Levemir® | Mannkind Corporation, Jaeb Center for Health Research | Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2 | 10/24 | 05/25 | | |
NCT05493709: Efficacy, Safety, and Pharmacokinetics of Leuprolide Mesylate in Subjects with Central Precocious Puberty |
|
|
| Recruiting | 3 | 93 | US, RoW | Leuprolide Mesylate, Subcutaneous injection of 42 mg Leuprolide | Foresee Pharmaceuticals Co., Ltd., QPS Holdings LLC, Changchun GeneScience Pharmaceutical Co., Ltd. | Puberty; Precocious, Central | 11/25 | 06/26 | | |
DIAGNODE-3, NCT05018585 / 2021-002731-32: A Phase III Study to Investigate If the Study Drug Diamyd Can Preserve Insulin Production and Improve Glycemic Control in Patients Newly Diagnosed with Type 1 Diabetes |
|
|
| Recruiting | 3 | 330 | Europe, US, RoW | Recombinant human glutamic acid decarboxylase (rhGAD65) formulated in Alhydrogel®, Diamyd, Colecalciferol 2000 IU, Divisun 2000 IU, Placebo | Diamyd Medical AB | Type 1 Diabetes Mellitus | 12/27 | 12/27 | | |
JANUS, NCT05610163: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation |
|
|
| Recruiting | 2 | 312 | US | Capecitabine, 5-fluorouracil, Leucovorin calcium, Irinotecan, Oxaliplatin, Long Course Chemoradiotherapy, Computed Tomography, Magnetic Resonance Imaging, Sigmoidoscopy, biopsy | Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI) | Locally Advanced Rectal Carcinoma, Stage II Rectal Cancer AJCC V8, Stage III Rectal Cancer AJCC V8 | 09/25 | 09/32 | | |
| Recruiting | 1 | 40 | US | Continuous Theta Burst in Transcranial Magnetic Stimulation, cTBS, TMS, Neuromodulation | Vanderbilt University Medical Center, Vanderbilt Kennedy Center | Autism Spectrum Disorder, Catatonia, Intellectual Disability | 08/25 | 08/26 | | |
NCT03764514: Spinal Cord Stimulation in Chemotherapy Induced Neuropathy |
|
|
| Completed | N/A | 5 | US | Spinal Cord Stimulator | Prisma Health-Upstate | Chemotherapy-induced Peripheral Neuropathy | 05/22 | 05/22 | | |
NCT04984473: A Study to Evaluate Breathing Muscle Training in Cardiac Rehab |
|
|
| Recruiting | N/A | 42 | US | Inspiratory muscle training | Mayo Clinic | Healthy, Heart Failure | 06/25 | 06/25 | | |
| Recruiting | N/A | 68 | US | Inspiratory Muscle Training | Mayo Clinic, National Heart, Lung, and Blood Institute (NHLBI) | Heart Failure | 04/28 | 04/28 | | |
| Huang, Liang |
NCT05871437: Huaier Granule on Reducing the Level of Tumor Markers in Patients With Early-stage Breast Cancer |
|
|
| Recruiting | 4 | 379 | RoW | Huaier granule, Z20000109（NMPA Approval Number） | Fudan University, LinkDoc Technology (Beijing) Co. Ltd., Huazhong University of Science and Technology | Early-stage Breast Cancer | 10/24 | 08/25 | | |
BELIEVE-01, NCT05234684: A Study of Orelabrutinib Plus R-CHOP in Treatment-naïve Patients With MCD Subtype Diffuse Large B-cell Lymphoma |
|
|
| Recruiting | 3 | 150 | RoW | Orelabrutinib + R-CHOP, ICP-022+ R-CHOP, Placebo + R-CHOP | Beijing InnoCare Pharma Tech Co., Ltd. | Diffuse Large B Cell Lymphoma (DLBCL) | 07/24 | 12/25 | | |
NCT04586478: Phase II Clinical Trial of CNCT19 Cell Injection in the Treatment of Relapsed or Refractory Non-Hodgkin's Lymphoma |
|
|
| Recruiting | 2 | 60 | RoW | single dose of CNCT19 | Juventas Cell Therapy Ltd. | Non-Hodgkin's Lymphoma | 12/24 | 09/25 | | |
NCT05334823: A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents |
|
|
| Recruiting | 2 | 100 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia | 12/24 | 07/25 | | |
| Recruiting | 1/2 | 120 | RoW | Chidamide, HDACi, Fludarabine and cyclophosphamide, FC regimen, Anti-CD19 CAR-T cells, Relma-cel, Axi-cel, Other commercial CAR-T cells, Experimental CAR-T cells | Chinese PLA General Hospital | Non Hodgkin's Lymphoma | 06/24 | 06/25 | | |
NCT04888442: Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL |
|
|
| Recruiting | 1 | 18 | RoW | pCAR-19B cells | Chongqing Precision Biotech Co., Ltd | Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia | 01/22 | 03/22 | | |
NCT05398614: SENL101 Autologous T Cell Injection in Adults With Relapsed or Refractory CD7+ Hematolymphoid Malignancies |
|
|
| Recruiting | 1 | 18 | RoW | SENL101 | Hebei Senlang Biotechnology Inc., Ltd. | T-ALL, Lymphoma, T-Cell | 12/23 | 06/24 | | |
NCT05388695: To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors |
|
|
| Recruiting | 1 | 100 | RoW | Autologous CD19/CD22/CD20 Chimeric Antigen Receptor T-cells | Hebei Senlang Biotechnology Inc., Ltd., Hebei Taihe Chunyu Biotechnology Co., Ltd | 19 and 22+ B Cell Hematologic Tumors, 19 and 20+ B Cell Hematologic Tumors | 03/25 | 05/25 | | |
NCT05109130: Change of Circulating Tumor Cells During Laparoscopic or Transanal Endoscopic Surgery for Rectal Cancer. |
|
|
| Active, not recruiting | N/A | 100 | RoW | Surgical approach | Sun Yat-sen University | Rectal Neoplasms, Neoplastic Cells, Circulating, Laparoscopic Surgery, Transanal Endoscopic Surgery | 10/22 | 10/25 | | |
NCT06142175: Relmacabtagene Autoleucel in Patients With LBCL |
|
|
| Recruiting | N/A | 200 | RoW | Relmacabtagene Autoleucel, JWCAR029 | Shanghai Ming Ju Biotechnology Co., Ltd. | Large B-cell Lymphoma | 12/24 | 12/24 | | |
NCT05201885: Oncological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer. |
|
|
| Recruiting | N/A | 192 | RoW | | Yanhong Deng | Rectum Cancer | 02/23 | 02/26 | | |
NCT05201872: Bacteriological Differences Between Transanal and Laparoscopic Total Mesorectal Excision for Rectal Cancer. |
|
|
| Recruiting | N/A | 216 | RoW | | Yanhong Deng | Rectum Cancer | 02/23 | 04/23 | | |
NCT05388305: Universal CAR-γδT Cell Injection in the AML Patients |
|
|
| Recruiting | N/A | 30 | RoW | CAR--γδT cells | Hebei Senlang Biotechnology Inc., Ltd. | AML | 04/23 | 05/23 | | |
| Completed | N/A | 1006 | RoW | | Takeda | Lymphoma | 07/24 | 07/24 | | |
NCT06036862: Utilization of Transanal Endoscopy in the Treatment of Anastomotic Stenosis |
|
|
| Recruiting | N/A | 50 | RoW | Transanal and transabdominal combined endoscopic resection of rectal stenosis and anal reconstruction | Sun Yat-sen University | Anastomotic Stenosis | 12/26 | 12/26 | | |
| Zhang, Huilan |
| Terminated | 3 | 372 | Europe, US, RoW | Pamrevlumab, FG-3019, Placebo | FibroGen | Idiopathic Pulmonary Fibrosis | 09/23 | 09/23 | | |
|
NCT05895565: A Multiple Ascending Doses (MAD) Study of PMG1015 in Idiopathic Pulmonary Fibrosis Subjects |
|
|
| Recruiting | 1 | 28 | RoW | PMG1015, PMG1015 placebo | Pulmongene Ltd. | IPF | 12/24 | 05/25 | | |
| Hu, Guangyuan |
JADE, NCT06256588: A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 3 | 864 | Europe, Canada, Japan, US, RoW | Dostarlimab, Placebo | GlaxoSmithKline | Neoplasms, Head and Neck | 05/28 | 07/29 | | |
| Recruiting | 3 | 500 | Europe, Canada, Japan, US, RoW | NBTXR3, Functionalized hafnium oxide nanoparticles, Cetuximab, Erbitux, Radiation Therapy | Nanobiotix, Nanobiotix SA | Locally Advanced Head and Neck Squamous Cell Carcinoma, Aged | 06/26 | 06/27 | | |
NCT06235918: Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 30 | RoW | Tislelizumab, BGB-A317, Nab-paclitaxel, Carboplatin | Xiang Lu | Head and Neck Squamous Cell Carcinomas, Resectable Head and Neck Squamous-cell Carcinoma | 01/25 | 01/26 | | |
NCT05145907: Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors |
|
|
| Active, not recruiting | 2 | 133 | RoW | TJ107 +Pembrolizumab | TJ Biopharma Co., Ltd. | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 06/24 | 12/24 | | |
NCT04600817: A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard Concurrent Chemoradiotherapy (CCRT) |
|
|
| Active, not recruiting | 2 | 160 | RoW | TJ107, TJ107 placebo | TJ Biopharma Co., Ltd. | Newly Diagnosed Glioblastoma | 12/24 | 12/24 | | |
NCT06236997: Adebrelimab and Concurrent Radiochemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer |
|
|
| Not yet recruiting | 2 | 48 | RoW | Adebrelimab, Radiation Therapy, etoposide, carboplatin(EC) | Henan Cancer Hospital, Huazhong University of Science and Technology | Small Cell Lung Carcinoma | 05/26 | 12/27 | | |
HLX10HLX07-001, NCT04297995: Evaluate the Efficacy and Safety of HLX10 in Combination With HLX07 in Patients With Advanced Head and Neck Tumors |
|
|
| Active, not recruiting | 2 | 131 | RoW | HLX10, HLX07, HLX07 placebo, Cisplatin/Carboplatin, 5-FU | Shanghai Henlius Biotech | Head and Neck Squamous Cell Carcinoma | 05/24 | 06/25 | | |
NCT06378177: A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC) |
|
|
| Recruiting | 2 | 64 | RoW | LVGN6051 Monoclonal Antibody Injection, LVGN6051, toripalimab Injection, Paclitaxel injection | Lyvgen Biopharma Holdings Limited | Head and Neck Squamous Cell Carcinoma | 10/27 | 10/27 | | |
NCT06097793: KSD-101 Therapy for EBV-associated Nasopharyngeal Carcinoma: an Exploratory Clinical Trial |
|
|
| Recruiting | 1 | 12 | RoW | KSD-101 | Kousai Bio Co., Ltd. | Nasopharyngeal Carcinoma | 12/24 | 12/25 | | |
NCT06737146: Study of MT027 in Patients with Recurrent or Progressive High-grade Glioma |
|
|
| Not yet recruiting | 1 | 12 | RoW | MT027 cells suspension | Suzhou Maximum Bio-tech Co., Ltd. | High-grade Glioma | 06/26 | 12/26 | | |
| Wei, Juncheng |
| Recruiting | 1 | 216 | RoW | BAT8006 for Injection, Exatecan conjugate of recombinant humanized monoclonal antibody against folate receptor α for injection | Bio-Thera Solutions | Advanced Solid Tumors | 12/24 | 12/25 | | |
